Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | YAP1 | P46937 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599540 | 0.93 | PTPN1 (0.36) | GPR132CXCR2TRPV1PTPN1YAP1 | |
| SCHEMBL25599046 | 0.92 | CXCR2 (0.41) | GPR132CXCR2TRPV1PTPN1YAP1 | |
| SCHEMBL25599106 | 0.91 | CXCR2 (0.42) | GPR132CXCR2PTPN1YAP1PPARD | |
| SCHEMBL25599487 | 0.90 | GPR132 (0.34) | GPR132CXCR2TRPV1PTPN1ITGB3 | |
| SCHEMBL25599550 | 0.87 | CXCR2 (0.30) | CXCR2 | |
| SCHEMBL25599423 | 0.86 | CXCR2 (0.41) | GPR132CXCR2PTPN1YAP1PPARD | |
| SCHEMBL25599537 | 0.84 | CXCR2 (0.41) | GPR132CXCR2PTPN1ACE | |
| SCHEMBL25599284 | 0.83 | CXCR2 (0.51) | GPR132CXCR2PTPN1YAP1ACE | |
| SCHEMBL25599374 | 0.83 | CXCR2 (0.51) | GPR132CXCR2PTPN1YAP1ACE | |
| SCHEMBL25599235 | 0.83 | CXCR2 (0.40) | GPR132CXCR2PTPN1YAP1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159439-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | GPR132 750/4885CXCR2 1205/4885TRPV1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.